Considering all findings, TCE treatment mitigated scopolamine-induced memory impairment by reducing proinflammatory cytokines and GFAP expression while concurrently increasing 5-HT concentration and neuronal density in the hippocampus. The gene discussed is GFAP; the disease is memory impairment.